NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free SRPT Stock Alerts $123.97 +0.92 (+0.75%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$122.33▼$125.4150-Day Range$102.61▼$141.5352-Week Range$55.25▼$159.89Volume523,103 shsAverage Volume1.15 million shsMarket Capitalization$11.64 billionP/E RatioN/ADividend YieldN/APrice Target$159.35 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside28.5% Upside$159.35 Price TargetShort InterestBearish5.09% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.51Based on 10 Articles This WeekInsider TradingSelling Shares$2.74 M Sold Last QuarterProj. Earnings Growth342.70%From $1.85 to $8.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.78 out of 5 starsMedical Sector44th out of 947 stocksPharmaceutical Preparations Industry15th out of 435 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $159.35, Sarepta Therapeutics has a forecasted upside of 28.5% from its current price of $123.97.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.09% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 0.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 1.9 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search Interest42 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,739,419.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions91.82% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 342.70% in the coming year, from $1.85 to $8.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 13.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesMarch 16, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo Sells 3,135 SharesMarch 12, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Kathryn Jean Boor Sells 761 SharesMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 12, 2024 | insidertrades.comHans Lennart Rudolf Wigzell Sells 15,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) StockMarch 18, 2024 | americanbankingnews.comQ1 2025 EPS Estimates for Sarepta Therapeutics, Inc. Cut by Zacks Research (NASDAQ:SRPT)March 13, 2024 | markets.businessinsider.comBuy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic PartnershipsMarch 13, 2024 | fool.comDoes This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?March 12, 2024 | finance.yahoo.comDirector Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)March 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 12, 2024 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Hans Lennart Rudolf Wigzell Sells 15,000 Shares of StockMarch 9, 2024 | americanbankingnews.comInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells 3,135 Shares of StockMarch 9, 2024 | uk.finance.yahoo.comSRPT Mar 2024 80.000 putMarch 8, 2024 | fool.comGot $1,000? Buy These Hot Growth Stocks Before They Take Off.March 7, 2024 | finance.yahoo.comDirector Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)March 6, 2024 | markets.businessinsider.comSarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging CompetitorsMarch 4, 2024 | fool.comSarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street AnalystMarch 4, 2024 | businesswire.comSarepta Therapeutics to Present at Upcoming Investor ConferencesMarch 2, 2024 | finance.yahoo.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMarch 2, 2024 | gurufocus.comDecoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT InsightMarch 1, 2024 | seekingalpha.comSarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising OutlookMarch 1, 2024 | finance.yahoo.comSarepta Therapeutics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 29, 2024 | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 29, 2024 | finance.yahoo.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | businesswire.comSarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship ProgramFebruary 29, 2024 | fool.comSarepta Therapeutics (SRPT) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comSarepta Therapeutics Q4 Earnings SummarySee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/18/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$159.35 High Stock Price Target$224.00 Low Stock Price Target$109.00 Potential Upside/Downside+27.6%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($6.12) Trailing P/E RatioN/A Forward P/E Ratio67.52 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins-43.11% Pretax Margin-41.83% Return on Equity-18.97% Return on Assets-4.65% Debt Debt-to-Equity Ratio1.32 Current Ratio3.95 Quick Ratio3.45 Sales & Book Value Annual Sales$1.24 billion Price / Sales9.43 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book13.59Miscellaneous Outstanding Shares93,900,000Free Float86,951,000Market Cap$11.73 billion OptionableOptionable Beta0.94 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRLegend BiotechNASDAQ:LEGNKaruna TherapeuticsNASDAQ:KRTXCatalentNYSE:CTLTDr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 243,180 shares on 3/11/2024Ownership: 9.429%Kathryn Jean BoorSold 761 sharesTotal: $93,549.73 ($122.93/share)Hans Lennart Rudolf WigzellSold 15,000 sharesTotal: $1.85 M ($123.25/share)Wellington Management Group LLPBought 217,810 shares on 3/5/2024Ownership: 4.398%Stephen MayoSold 3,135 sharesTotal: $385,479.60 ($122.96/share)View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 16 brokers have issued 12 month price targets for Sarepta Therapeutics' stock. Their SRPT share price targets range from $109.00 to $224.00. On average, they anticipate the company's share price to reach $159.35 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2024? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT shares have increased by 28.6% and is now trading at $123.97. View the best growth stocks for 2024 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.50. The biotechnology company earned $396.80 million during the quarter, compared to analysts' expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative trailing twelve-month return on equity of 18.97%. The company's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.24) earnings per share. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.42%), Vanguard Group Inc. (9.43%), Capital International Investors (5.07%), Avoro Capital Advisors LLC (4.64%), Wellington Management Group LLP (4.40%) and Norges Bank (0.89%). Insiders that own company stock include Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.